- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- AJANTA PHARMA LTD. (pharmaceuticals)
- Latest 8 Quarter Result
AJANTA PHARMA Quarterly Results 
(AJPH)
Here are the latest quarterly results of AJANTA PHARMA. For more details, see the AJANTA PHARMA financial fact sheet and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
AJANTA PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-17* |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 4,768 | 4,731 | 5,404 | 5,871 | 5,303 | 5,110 | 5,441 | 4,851 | |
| Other income | Rs m | 24 | 48 | 92 | 152 | 52 | 81 | 152 | 44 | |
| Turnover | Rs m | 4,792 | 4,779 | 5,496 | 6,022 | 5,356 | 5,191 | 5,594 | 4,895 | |
| Expenses | Rs m | 3,154 | 3,457 | 3,567 | 3,896 | 3,908 | 3,535 | 3,779 | 3,778 | |
| Gross profit | Rs m | 1,614 | 1,275 | 1,837 | 1,975 | 1,395 | 1,575 | 1,662 | 1,073 | |
| Depreciation | Rs m | 189 | 134 | 146 | 150 | 166 | 172 | 175 | 187 | |
| Interest | Rs m | 9 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | |
| Profit before tax | Rs m | 1,440 | 1,187 | 1,783 | 1,975 | 1,280 | 1,483 | 1,638 | 930 | |
| Tax | Rs m | 300 | 239 | 464 | 501 | 335 | 425 | 385 | 261 | |
| Profit after tax | Rs m | 1,140 | 948 | 1,319 | 1,475 | 945 | 1,058 | 1,254 | 669 | |
| Gross profit margin | % | 33.8 | 26.9 | 34.0 | 33.6 | 26.3 | 30.8 | 30.5 | 22.1 | |
| Effective tax rate | % | 20.8 | 20.2 | 26.0 | 25.3 | 26.2 | 28.7 | 23.5 | 28.0 | |
| Net profit margin | % | 23.9 | 20.0 | 24.4 | 25.1 | 17.8 | 20.7 | 23.0 | 13.8 | |
| Diluted EPS | Rs | 13.0 | 10.8 | 15.0 | 16.8 | 10.7 | 12.0 | 14.3 | 7.6 | |
| Diluted EPS (TTM) | Rs | 57.6 | 54.8 | 55.0 | 55.5 | 53.3 | 54.5 | 53.8 | 44.6 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: AJANTA PHARMA 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: AUROBINDO PHARMA ALEMBIC PHARMA SUN PHARMA DIVIS LABORATORIES ALKEM LABORATORIES
Compare AJANTA PHARMA With: AUROBINDO PHARMA ALEMBIC PHARMA SUN PHARMA DIVIS LABORATORIES ALKEM LABORATORIES
Compare AJANTA PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Of Oil Prices Hitting New Highs; Jet Airways' Bailout Plan, and Top Stocks in Action Today(Pre-Open)
On Friday, share markets in India traded on a negative note throughout the day and ended marginally lower after a volatile day of trading.
Views on news
AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)
Feb 1, 2019 | Updated on Feb 1, 2019For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)
Nov 6, 2018 | Updated on Nov 6, 2018For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)
Feb 5, 2019A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
More|
| |
AJANTA PHARMA SHARE PRICE
Feb 15, 2019 (Close)
TRACK AJANTA PHARMA
- Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AJANTA PHARMA
AJANTA PHARMA 5-YR ANALYSIS
COMPARE AJANTA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.